Sobi to cease ReFacto manufacturing in the first quarter of 2024
Sobi® today announced that its contract with Pfizer for the manufacture of drug substance for ReFacto AF®/Xyntha® (ReFacto) has been amended due to clarity of final order volumes and will now expire in the first quarter of 2024, earlier than the previous expiry date at the end of 2025. Manufacturing of drug substance for ReFacto will be transferred to Pfizer’s production unit in Ireland, ensuring continued patient access. Sobi will start the process of downsizing its Stockholm manufacturing facility in the second half of 2022, with the last volumes being delivered to Pfizer in the